Navigation Links
XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
Date:6/30/2008

nt.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >XTLB; TASE: XTL).

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for our clinical compound for neuropathic pain, Bicifadine, the likelihood of successful results from a clinical trial with Bicifadine, operating strategies and similar matters, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete the Phase 2b clinical trial with Bicifadine and obtain positive trial results from the Phase 2b clinical trial, all of which will directly impact our ability to continue to fund our operations; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission, including our annual report on Form 20-F filed with the Securities and Exchange Commission on March 27, 2008. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.xtlbio.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
2. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
5. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
6. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
7. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
8. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
9. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... HILL, Conn. , July 29, 2014 Numotion,s ... 2014, Mike Swinford will be the company,s new ... a highly successful 22-year career at GE where he worked ... million in annual revenue to over $5 billion. His most ... Global Services. "I am thrilled to join ...
(Date:7/29/2014)... , July 29, 2014 McGraw-Hill Education ... for the science, technical, and medical communities, has announced ... first off-line mobile application of the world-renowned medical education ... new AccessMedicine App , available for download onto ... now be able to gain access to valuable ...
(Date:7/29/2014)... 29, 2014  Neurocrine Biosciences, Inc. (Nasdaq: ... its second quarter 2014 financial results after the Nasdaq ... then host a live conference call and webcast to ... Thursday morning, August 7, 2014 at 8:00 a.m. Eastern ... access the live conference call by dialing 866-952-1907 (US) ...
Breaking Medicine Technology:Numotion Names Mike Swinford CEO 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2
... China, Dec. 16, 2010 /PRNewswire-Asia-FirstCall/ -- China Botanic Pharmaceutical ... the "Company"), a developer, manufacturer and distributor of botanical ... that Mr. David Dong was named the Company,s new ... Mr. Dong,s career spans over 10 years ...
... Dec. 16, 2010 WaferGen Biosystems, Inc. (OTC Bulletin ... state-of-the-art genomic analysis systems, and the Integrated BioBank of ... strategic relationship that will expand the use of the ... personalized medicine.   The agreement includes: ...
Cached Medicine Technology:China Botanic Appoints David Dong as New Chief Financial Officer 2China Botanic Appoints David Dong as New Chief Financial Officer 3WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 2WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 3WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 4WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 5
(Date:7/29/2014)... Premier Women’s Health , a six-physician ... has affiliated with Allegheny Health Network’s renowned Women’s Health ... babies and perform surgical procedures at Heritage Valley Sewickley. ... referred to Allegheny Health Network’s West Penn Hospital ... West Penn Hospital and its highly regarded Women’s Health ...
(Date:7/29/2014)... IsoComforter, Inc ., one of ... today the introduction of the innovative new Iso-Hip Wrap. ... created for post operative hip replacement patients. The plush ... the benefits of cold therapy while resting, sitting, or ... replacements are done every year. Cold therapy is ...
(Date:7/29/2014)... According to the new market research report, ... Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application ... Banking & Finance), and Geography - Global Trends ... MarketsandMarkets, the global Fingerprint Sensors Market is projected ... a high CAGR of 16.8% from 2014 to ...
(Date:7/29/2014)... 29, 2014 Test instruments after ... and protein soils where it matters most – ... leading manufacturer of premium domestic appliances, introduces ProCare ... instruments are effectively cleaned. The ProCare liquid is ... immediately after processing. After 3 minutes, users visually ...
(Date:7/29/2014)... (CA) method is in principle suitable to find out ... widely use it in health economic evaluations, some (primarily ... the result of a pilot project by the German ... Following the Analytic Hierarchy Process (AHP), CA is the ... experts. , Summarize outcome-specific results to an overall ...
Breaking Medicine News(10 mins):Health News:Leading West Suburban OBGYN Practice, Premier Women’s Health, Joins Allegheny Health Network 2Health News:Leading West Suburban OBGYN Practice, Premier Women’s Health, Joins Allegheny Health Network 3Health News:New IsoComforter Cold Therapy Unit Plus Hip Wrap Gives Post Operative Hip Replacement Patients Faster Recovery Times 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 4Health News:ProCare Protein Check Tests Surgical Instruments to Verify Effective Cleaning 2Health News:Determine patient preferences by means of conjoint analysis 2Health News:Determine patient preferences by means of conjoint analysis 3Health News:Determine patient preferences by means of conjoint analysis 4
... Unhappy marriages are harmful to the self-esteem and health of ... to higher levels of psychological distress when compared to those ... as many as 1,150 people in unhappy // marriages ... of sociology, human development and family studies, and demography said ...
... the heart with the progress of age can be postponed by ... which the Journal of the American College of Cardiology has published. ... primary aging can // be delayed by restricting calories in human ... fact has already been proved in the case of small mammals. ...
... regard to the hormone replacement therapy (HRT), another research has put ... to the heart. //The risk of a coronary heart disease is ... the HRT at an younger age, when in comparison to women ... cardiovascular benefits to be seen in the case of women who ...
... Stetson have reported in the Journal Immunity that the host ... infection. // ,Viruses are classified based on their ... found that immune response which acts in recognisation of these ... RNA viruses. ,Immune response against the virus acts ...
... Professor Harvey Lodish and his post-doc Chengcheng Zhang from Whitehead ... of growth factors// which enriches and increases the number of ... into the recipient. ,Stem cell therapy as ... therapy is very high and it requires isolating large number ...
... Neurone Disease (MND), a fatal nerve disease could be improved ... ,Patients suffering from Motor Neurone Disease (MND) could ... works by helping people with MND who suffer from weakness ... reported. ,At present just one drug is licensed ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: